other material
confidence high
sentiment positive
materiality 0.75
Centessa ORX750 Phase 1 restores normative wakefulness at 2.5 mg, no hepatotoxicity; Phase 2 in Q4
Centessa Pharmaceuticals plc
- 2.5 mg dose achieved mean sleep latency of 32 min on MWT vs placebo 17 min (p=0.01), restoring normative wakefulness.
- No hepatotoxicity, visual disturbances, or common OX2R agonist AEs observed; all AEs mild/transient.
- 1.0 mg also statistically significant: mean sleep latency 18 min vs placebo 10 min (p=0.04).
- Plans to initiate Phase 2 studies in narcolepsy NT1, NT2, and idiopathic hypersomnia in Q4 2024.
- Linear PK supports once-daily dosing; systemic exposure dose-proportional.